Treats Attention Deficit Hyperactivity Disorders (ADHD) and Narcolepsy. ANDA 209276, held by Aurolife Pharma. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 209276 (Methylphenidate Hydrochloride), held by Aurolife Pharma, was first approved by FDA on Oct 25, 2018, with 1 approved supplement and 0 published complete response letters.
Methylphenidate Hydrochloride Tablets is indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 25, 2018 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride5MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride10MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Methylphenidate Hydrochloride20MG · tablet;oral | Methylphenidate Hydrochloride | Discontinued |
| Oct 16, 2026 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 25, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters